Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Genzyme, 31 Mar 2009
Accessed on 6 Dec 2011 from http://www.genzyme.com/corp/media/GENZ%20PR-033109.asp.